Summary

CYP2C19 determines how you metabolise clopidogrel (a pro-drug that REQUIRES activation), proton pump inhibitors, and several antidepressants — poor metabolisers (2/2) face life-threatening stent thrombosis risk on clopidogrel, while ultrarapid metabolisers (17/17) may burn through PPIs too fast for adequate acid suppression.

Genotype spectrum

GG

Standard clopidogrel activation. PPIs metabolised normally.

GA

~40% reduced clopidogrel activation. Higher residual platelet reactivity.

AA

Clopidogrel is essentially INEFFECTIVE. Cannot activate the pro-drug.

CC

Standard drug metabolism.

CT

Enhanced clopidogrel activation (beneficial). PPIs metabolised faster — may need higher PPI dose.

TT

Maximum clopidogrel activation. PPIs cleared too fast — standard doses may provide inadequate acid suppression.

Practical takeaway

For Poor Metabolisers (2/2)

Critical — clopidogrel is INEFFECTIVE for you:
• If prescribed clopidogrel (Plavix) for any indication — coronary stent, acute coronary syndrome, stroke prevention — inform your cardiologist of CYP2C19 poor metaboliser status immediately.
• Alternative antiplatelet agents: prasugrel (Effient) or ticagrelor (Brilinta) do NOT require CYP2C19 activation.
• This is especially critical post-percutaneous coronary intervention (PCI/stent placement), where clopidogrel failure can cause stent thrombosis — a medical emergency with high mortality.

PPIs — paradoxically advantageous:
• You achieve higher drug levels on standard PPI doses. This means better acid suppression and higher H. pylori eradication rates.
• For maintenance therapy, you may need lower PPI doses. Discuss with prescriber.

Antidepressants:
• Escitalopram and sertraline may accumulate. Start at lower doses. Monitor for side effects (serotonergic symptoms, GI disturbance).
• Some benzodiazepines (diazepam, clobazam) are also CYP2C19 substrates — slower clearance expected.
For Intermediate Metabolisers (1/2 or 2/17)
• Clopidogrel efficacy is reduced but not eliminated. Current CPIC guidelines recommend considering prasugrel or ticagrelor, particularly for high-risk stent patients.
• PPI and antidepressant metabolism modestly affected — standard dosing usually adequate but monitor response.
For Ultrarapid Metabolisers (17/17)

PPI dose awareness:
• Standard PPI doses (omeprazole, pantoprazole, lansoprazole, esomeprazole) may be metabolised too quickly for adequate acid suppression.
• If PPIs seem ineffective, request rabeprazole — it is primarily metabolised by CYP3A4 and less affected by CYP2C19 ultrarapid status.
• Alternatively, higher PPI doses or twice-daily dosing may be needed.

Clopidogrel — enhanced activation:
• You generate more active metabolite. This is generally beneficial for antiplatelet effect.
• Theoretical increased bleeding risk, though clinical significance is debated.

Antidepressants:
• May achieve subtherapeutic levels of escitalopram/sertraline at standard doses. If poor response, dose increase or alternative SSRI may be needed.

Evidence detail

What This Gene Does

CYP2C19 is a liver enzyme in the cytochrome P450 family responsible for metabolising approximately 10% of commonly prescribed drugs. Its most clinically significant substrate is clopidogrel (Plavix) — an antiplatelet pro-drug that is pharmacologically INACTIVE until CYP2C19 converts it to its active thiol metabolite. Without adequate CYP2C19 activity, clopidogrel cannot prevent blood clots.

The 2 allele (rs4244285, G>A) introduces a splice defect that produces a non-functional enzyme. The 17 allele (rs12248560, C>T) is a gain-of-function variant in the promoter region that increases gene transcription, producing more enzyme and faster metabolism. These two variants create a spectrum from poor to ultrarapid metabolism with direct consequences for drug efficacy and safety.

Mechanism

CYP2C19 sits in the endoplasmic reticulum of hepatocytes and performs oxidative metabolism of its substrates:

Clopidogrel activation (two-step):
1. Clopidogrel (inactive thienopyridine pro-drug) → 2-oxo-clopidogrel (intermediate) — CYP2C19 catalyses ~45% of this first step.
2. 2-oxo-clopidogrel → active thiol metabolite — CYP2C19 catalyses ~20% of this second step.
3. The active metabolite irreversibly binds platelet P2Y12 receptors, preventing ADP-mediated platelet aggregation for the platelet's 7-10 day lifespan.

Without functional CYP2C19, insufficient active metabolite is generated. Platelets remain reactive. Blood clots form on stent struts. Stent thrombosis is often fatal.

**The *2 allele mechanism:** rs4244285 (681G>A) creates an aberrant splice site in exon 5, producing a truncated, non-functional protein. One copy (1/2) halves functional enzyme; two copies (2/2) eliminates it.

**The *17 allele mechanism:** rs12248560 (-806C>T) increases CYP2C19 gene transcription by altering a regulatory element in the 5'-flanking region. More mRNA → more enzyme → faster substrate clearance.

CYP2C19

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (6)